dc.contributor.author |
Semete, B
|
|
dc.contributor.author |
Kalombo, Lonji
|
|
dc.contributor.author |
Katata, L
|
|
dc.contributor.author |
Chelule, P
|
|
dc.contributor.author |
Booysen, L
|
|
dc.contributor.author |
Lemmer, Yolandy
|
|
dc.contributor.author |
Naidoo, Saloshnee
|
|
dc.contributor.author |
Ramalapa, B
|
|
dc.contributor.author |
Hayeshi, R
|
|
dc.contributor.author |
Swai, HS
|
|
dc.date.accessioned |
2012-12-05T11:17:51Z |
|
dc.date.available |
2012-12-05T11:17:51Z |
|
dc.date.issued |
2012-03 |
|
dc.identifier.citation |
Semete, B., Kalombo, L., Katata, L., Chelule, P., Booysen, L., Lemmer, Y., Naidoo, S., Ramalapa, B., Hayeshi, R. and Swai, H.S. 2012. Potential of improving the treatment of tuberculosis through nanomedicine. Molecular Crystals and Liquid Crystals, Vol 556(1), pp 317-330 |
en_US |
dc.identifier.issn |
1542-1406 |
|
dc.identifier.uri |
http://www.tandfonline.com/doi/abs/10.1080/15421406.2012.635531
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/6396
|
|
dc.description |
Copyright: 2012 Taylor & Francis. This is the pre print version of the work. The definitive version is published in the journal of Molecular Crystals and Liquid Crystals, Vol 556(1), pp 317-330. |
en_US |
dc.description.abstract |
Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200–300 nm were synthesized, with a drug encapsulation efficiency of 50–65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Taylor & Francis |
en_US |
dc.relation.ispartofseries |
Workflow;8759 |
|
dc.subject |
Drug release |
en_US |
dc.subject |
Nanomedicine |
en_US |
dc.subject |
PLGA nanoparticles |
en_US |
dc.subject |
Tuberculosis |
en_US |
dc.title |
Potential of improving the treatment of tuberculosis through nanomedicine |
en_US |
dc.type |
Article |
en_US |
dc.identifier.apacitation |
Semete, B., Kalombo, L., Katata, L., Chelule, P., Booysen, L., Lemmer, Y., ... Swai, H. (2012). Potential of improving the treatment of tuberculosis through nanomedicine. http://hdl.handle.net/10204/6396 |
en_ZA |
dc.identifier.chicagocitation |
Semete, B, Lonji Kalombo, L Katata, P Chelule, L Booysen, Yolandy Lemmer, Saloshnee Naidoo, B Ramalapa, R Hayeshi, and HS Swai "Potential of improving the treatment of tuberculosis through nanomedicine." (2012) http://hdl.handle.net/10204/6396 |
en_ZA |
dc.identifier.vancouvercitation |
Semete B, Kalombo L, Katata L, Chelule P, Booysen L, Lemmer Y, et al. Potential of improving the treatment of tuberculosis through nanomedicine. 2012; http://hdl.handle.net/10204/6396. |
en_ZA |
dc.identifier.ris |
TY - Article
AU - Semete, B
AU - Kalombo, Lonji
AU - Katata, L
AU - Chelule, P
AU - Booysen, L
AU - Lemmer, Yolandy
AU - Naidoo, Saloshnee
AU - Ramalapa, B
AU - Hayeshi, R
AU - Swai, HS
AB - Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200–300 nm were synthesized, with a drug encapsulation efficiency of 50–65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment.
DA - 2012-03
DB - ResearchSpace
DP - CSIR
KW - Drug release
KW - Nanomedicine
KW - PLGA nanoparticles
KW - Tuberculosis
LK - https://researchspace.csir.co.za
PY - 2012
SM - 1542-1406
T1 - Potential of improving the treatment of tuberculosis through nanomedicine
TI - Potential of improving the treatment of tuberculosis through nanomedicine
UR - http://hdl.handle.net/10204/6396
ER -
|
en_ZA |